Amendment To License, Development, Supply and Distribution AgreementLicense, Development, Supply and Distribution Agreement • August 3rd, 2011 • Allergan Inc • Pharmaceutical preparations
This Amendment to License, Development, Supply and Distribution Agreement (the “Amendment”), effective as of June 13, 2011 (the “Amendment Effective Date”) by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 11500 S. Eastern Ave., Ste. 240, Henderson, Nevada 89052 (“Spectrum”).
Amendment To License, Development, Supply and Distribution AgreementLicense, Development, Supply and Distribution Agreement • August 4th, 2011 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment to License, Development, Supply and Distribution Agreement (the “Amendment”), effective as of June 13, 2011 (the “Amendment Effective Date”) by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 11500 S. Eastern Ave., Ste. 240, Henderson, Nevada 89052 (“Spectrum”).
SECOND AMENDMENT OF THE LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Development, Supply and Distribution Agreement • February 28th, 2013 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECOND AMENDMENT OF THE LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (this “Second Amendment”) is made and effective as of January 29, 2013 (the “Second Amendment Effective Date”) by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”) and Spectrum Pharmaceuticals, Inc. (“Spectrum”), a Delaware corporation with its principal place of business at 11500 S. Eastern Avenue, Henderson, Nevada 89052. Allergan and Spectrum are collectively referred to herein as the “Parties” and individually as a “Party”.
LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Development, Supply and Distribution Agreement • March 19th, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • Hong Kong
Oncolytics and Licensee are referred to from time to time herein individually as a “Party” or collectively as the “Parties”.
LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT by and among ALLERGAN SALES, LLC, ALLERGAN USA, INC., ALLERGAN, INC. and SPECTRUM PHARMACEUTICALS, INC. dated October 28, 2008License, Development, Supply and Distribution Agreement • February 27th, 2009 • Allergan Inc • Pharmaceutical preparations • New York
**** Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
First Amendment to the License, Development, Supply and Distribution Agreement by and among Allergan Sales, LLC, Allergan USA, Inc., Allergan, Inc., and Spectrum Pharmaceuticals, Inc.License, Development, Supply and Distribution Agreement • May 8th, 2009 • Allergan Inc • Pharmaceutical preparations
This FIRST AMENDMENT (the “Amendment”) TO THE LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (the “Agreement”), entered into as of April 20, 2009 (the “Amendment Effective Date”), is made by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”) and Spectrum Pharmaceuticals, Inc. (“Spectrum”), a Delaware corporation with its principal place of business at 157 Technology Drive, Irvine, CA 92618.
LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Development, Supply and Distribution Agreement • March 15th, 2007 • Immunicon Corp • Laboratory analytical instruments • Delaware
This LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2006 (“Effective Date”) by and between IMMUNICON CORPORATION, a Delaware corporation, having its principal office at 3401 Masons Mill Road, Suite 100, Huntingdon Valley, PA 19006 and its subsidiaries (collectively, “Immunicon”), and DIAGNOSTIC HYBRIDS, INC., an Ohio corporation, having its principal office at 350 West State St., Athens, OH 45701 (“DHI”).
LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT by and among ALLERGAN SALES, LLC, ALLERGAN USA, INC., ALLERGAN, INC. and SPECTRUM PHARMACEUTICALS, INC. dated October 28, 2008License, Development, Supply and Distribution Agreement • March 31st, 2009 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
**** Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
